Clinical trials: Blood Plasma Therapy
Nasopharyngeal Carcinoma, NPC
Plasma EBV DNA Monitoring in Post-treatment NPC Patients
Continuous regular monitoring of plasma EBV DNA in nasopharyngeal carcinoma (NPC) after treatment have rarely been investigated.
- Conditions
- Nasopharyngeal Carcinoma, NPC, EBV, Radiotherapy
- Trial name
- NCT03973723
- Where
- Taiwan
- Volunteers
- 441 people
- Sponsor
- Taichung Veterans General Hospital
Multiple Myeloma
Lenalidomide Maintenance Therapy for Multiple Myeloma
Background: Multiple myeloma is rarely curable, but it is treatable. Initial treatment is directed at controlling symptoms and reducing the number of myeloma cells. It continues until the cancer stops responding to treatment.
- Trial name
- NCT01675141
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment.
- Trial name
- MASTER-2 (NCT05231629)
- Testing
- Dara-VRd intensification, Dara-R maintenance, AHCT intensification, Dara-R maintenance, AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance
- Where
- 10 sites in United States
- Volunteers
- 300 people
- Sponsor
- University of Alabama at Birmingham
Wegener's Granulomatosis, Microscopic Polyangiitis
Plasma Exchange for Renal Vasculitis
The purpose of this study is to test whether additional therapy with plasma exchange improves the chances of kidney recovery in severe kidney vasculitis.
- Trial name
- MEPEX (NCT01408836)
- Testing
- Plasma exchange, Intravenous methyl prednisolone, Methyl prednisolone
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Multiple Myeloma, Hypogammaglobulinemia
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).
- Conditions
- Multiple Myeloma, Hypogammaglobulinemia, Hypogammaglobulinemia, Acquired
- Trial name
- NCT06976476
- Testing
- IgPro20
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acne Vulgaris
Safety Study of Plasma Treatment System to Treat Back Acne
The purpose of this study is to evaluate the safety of treating human skin with atmospheric plasma and get an initial evaluation of the efficacy of this treatment for acne.
- Trial name
- NCT01662349
- Testing
- MOE Antimicrobial Plasma Treatment System
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Moe Medical Devices
Multiple Myeloma
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease activity of etentamig in…
- Trial name
- NCT06896916
- Testing
- Etentamig, Iberdomide
- Where
- 27 sites in United States, Australia and 5 more
- Volunteers
- 135 people
- Sponsor
- AbbVie
Dry Eye
Autologous Plasma Treatment for Severe Dry Eye Patients
Patients with severe dry eye who have exhausted conventional treatment are not uncommon and are difficult to manage. They and their physicians are helpless when faced with these scenarios.
- Trial name
- NCT03768115
- Testing
- Autologous Plasma Eye Drop
- Where
- Singapore
- Volunteers
- healthy volunteers welcome
- Sponsor
- Singapore National Eye Centre
Myeloma, Plasma-Cell, Myeloma-Multiple
Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma
Background: Cancer development is associated with problems in immune system functions, which prevent the body from attacking and destroying the abnormal cells that lead to tumor growth.
- Conditions
- Myeloma, Plasma-Cell, Myeloma-Multiple, Myelomatosis
- Trial name
- NCT01239368
- Testing
- Adoptive Immunotherapy, Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells), Th1/Tc1 Rapa Cell Therapy
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Relapsed, Multiple Myeloma, Refractory to Standard Treatment
TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)
In this phase I trial, patients with relapsed or refractory multiple myeloma will receive standard autologous stem cell transplant conditioned with high dose melphalan.
- Trial name
- BMT-03 (NCT02043847)
- Testing
- Total Marrow Irradiation, Melphalan, Filgrastim (G-CSF)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Illinois Chicago
Multiple Myeloma
2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
The Total Therapy treatment regimens developed at the Myeloma Institute have demonstrated great improvement in treatment outcomes for multiple myeloma patients.
- Trial name
- NCT03168100
- Testing
- Elotuzumab, Lenalidomide, Dexamethasone
- Where
- United States
- Sponsor
- University of Arkansas
Androgenetic Alopecia
Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia
Androgenetic alopecia (AGA) or common baldness is the most common cause of hair loss in both men and women and is caused by the action of androgens in genetically predisposed individuals.
- Trial name
- NCT01885676
- Testing
- PRGF-Endoret, Saline Solution
- Where
- 2 sites in Spain
- Sponsor
- Biotechnology Institute IMASD
Lymphoma, Myeloma
Acupuncture for Chemo-Induced Peripheral Neuropathy
The goal of this clinical research study is to learn if giving acupuncture to patients with lymphoma or a plasma cell dyscrasia can help to relieve numbness and/or tingling of the feet and/or hands that is related to chemotherapy.
- Conditions
- Lymphoma, Myeloma, Peripheral Neuropathy
- Trial name
- NCT00891618
- Testing
- Acupuncture
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Inflammatory Cytokines in Symptom Production in Multiple Myeloma
The goal of this research study is to learn about the pain and/or other symptoms that patients may experience either while you are being monitored by your doctor before a decision is made to start you on treatment for your MM, or…
- Trial name
- NCT00688168
- Testing
- Questionnaire, Neurocognitive Testing, Neurosensory Testing
- Where
- United States
- Volunteers
- 491 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma, Autologous Stem Cell Transplant
A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant
The purpose of this study is to determine the effect of ixazomib citrate maintenance therapy on progression-free survival (PFS), compared to placebo, in participants with newly diagnosed multiple myeloma (NDMM) who have had a…
- Trial name
- NCT02181413
- Testing
- Ixazomib Citrate
- Where
- 227 sites in United States, Argentina and 31 more
- Volunteers
- 656 people
- Sponsor
- Takeda
Lymphoma
Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma
RATIONALE: Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
- Trial name
- NCT00784927
- Testing
- rituximab, cyclophosphamide, dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic
Relapsed/Refractory Multiple Myeloma
Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
A prospective, open-label, single-arm clinical study of mitoxantrone hydrochloride liposome injection combined with daratumumab and dexamethasone in the treatment of relapsed/refractory multiple myeloma
- Trial name
- NCT05857982
- Testing
- Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Stroke, Acute, Biological Specimen Banks
Thrombus Composition in Ischemic Stroke: Analysis of the Correlation With Plasma Biomarkers, Efficacy of Treatment, Etiology and Prognosis
The recent validation of thrombectomy in addition to thrombolysis with intravenous administration of alteplase suggests a major revolution in the management of acute strokes.
- Conditions
- Stroke, Acute, Biological Specimen Banks, Biomarkers, Etiology
- Trial name
- COMPO-CLOT (NCT03268668)
- Testing
- Collection of thrombus that is responsible for stroke and blood sample
- Where
- 12 sites in France
- Volunteers
- 1,200 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Multiple Myeloma Stage I
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation
The best induction protocol to eligible multiple myeloma patients was not established. Combination of three drugs demonstrated better outcomes than two drugs combo.
- Trial name
- MAXDARA (NCT03792620)
- Testing
- Cyclo Thal Dex Daratumumab
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Grupo de Estudos Multicentricos em Onco-Hematologia
Knee OA
a Single HYAJOINT Plus Combined With a Single PPR Versus a Single PRP for Knee OA
Intraarticular hyaluronan or platelet-rich plasma (PRP) is each effective in the treatment for knee osteoarthritis (OA). The efficacy of combined hyaluronan with PRP for knee OA remained unclear.
- Trial name
- NCT04315103
- Testing
- a single intraarticular injection of HYAJOINT Plus (3 ml) followed by 3 ml PRP
- Where
- 2 sites in Taiwan
- Volunteers
- 85 people
- Sponsor
- Kaohsiung Veterans General Hospital.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.